LBT Innovations (ASX:LBT) - Managing Director & CEO, Brent Barnes
Managing Director & CEO, Brent Barnes
Source: LBT Innovations
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • LBT Innovations (LBT) has received firm commitments to raise $8 million via a share placement, adding several new institutional investors to the register
  • The Australian medical technology company has also launched a share purchase plan (SPP) with hopes to raise another $1 million
  • Funds from the placement and SPP will be directed towards accelerating commercialisation activities in Europe, including under a new marketing partnership with Beckman Coulter
  • Along with existing cash reserves, the capital raising will provide the company with a funding runway into 2022
  • LBT shares are trading flat for 19 cents each at open

LBT Innovations (LBT) has received firm commitments from sophisticated and professional investors to raise $8 million via a share placement.

The placement

The Australian medical technology company received these commitments from both existing shareholders and several new institutional investors.

Under the placement, LBT will issue 50 million new fully paid ordinary shares at an issue price of 16 cents each which represents a 21.9 per cent discount to the five-day volume-weighted average price.

The issue will not require shareholder approval, as the shares will be issued under the company’s existing placement capacity around July 15, 2020.

The Share purchase plan

LBT has also launched a share purchase plan (SPP) targeting an additional $1 million but has reserved the right to accept oversubscriptions.

Eligible shareholders will be able to subscribe for up to $30,000 worth of new shares for 16 cents per share.

Use of the funds

Funds from the placement and SPP will be directed towards accelerating commercialisation activities in Europe, including under a new marketing partnership with Beckman Coulter that was announced on Tuesday.

Additionally, the funds will support ongoing commercialisation activities in the United States, the development of the Automated Plate Assessment System (APAS) analysis module and provide working capital.

Along with the LBT’s $7.1 million in cash as at June 30, 2020, the capital raising will provide the company with a funding runway into 2022.

LBT shares are trading flat for 19 cents each at market open.

LBT by the numbers
More From The Market Online
Image of a woman holding a bottle of hemp oil

Little Green Pharma jumps into distribution with acquisition

Little Green Pharma is aiming to make the strategic acquisition of HH (Australia) Pty Ltd to…
Image of cancer cells

Radiopharm approved to start Lu-RAD202 safety trials, door open for in-human studies

Radiopharm Theranostics has received ethics approval for its trial into Lu-RAD202, a novel treatment for these…
Close up of a nasal spray

LTR Pharma pairs with Men’s Health Downunder for supply of erectile dysfunction spray

LTR Pharma Ltd has signed an agreement with Men's Health Downunder to facilitate supply of its…
Immune system concept ai gen

Immutep dips as safety test for flagship drug IMP761 shows no adverse effects

Immutep has reported a small-scale conceptual safety test among 5 patients using flagship drug IMP761 has…